As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate of 5.0% as the discount rate to calculate the present value of future lease payments, which was the interest rate that its bank would charge for a similar loan.
 See notes to unaudited condensed consolidated financial statements.
 The following table summarizes the Company’s disaggregation of revenues for the three months ended September 30, 2019 and 2018.
  The Company elected not to recognize a ROU asset and a lease liability for leases with an initial term of twelve months or less.
Some contracts call for training and installation, which is considered ancillary and not a material part of the contract.
  For the three months ended September 30, 2019 and 2018, respectively, three customers accounted for approximately 23% (both periods) of net sales of the Benchtop Laboratory Equipment Operations (18% and 19% of the Company’s total revenues).
Total cash payments under these leases were $68,400, of which $68,300 was recorded as leases expense.
Normally, the Company warrantees its instruments for a period of twelve months for parts and labor which normally consists of replacement of small components or software support.
All material intercompany balances and transactions have been eliminated.
2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less.
 See notes to unaudited condensed consolidated financial statements.Net cash used in investing activities was $25,700 for the three months ended September 30, 2019 compared to $4,900 used during the three months ended September 30, 2018 principally due to new capital equipment purchased during the current period by the Benchtop Laboratory Equipment Operations.
Commencing in the fourth quarter of the fiscal year ended June 30, 2019, the Company began committing significant resources for the Bioprocessing Systems Operations for new engineering personnel, market research, materials, supplies, and administration, and expects to continue to grow this business segment which will require substantial cash outlays.
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Consequently, no forward-looking statement can be guaranteed.
Net revenues for the three months ended September 30, 2019 decreased $34,400 (1.7%) to $2,004,200 from $2,038,600 for the three months ended September 30, 2018, reflecting a decrease of $115,700 (6.8%) decrease in net sales of Benchtop Laboratory Equipment primarily due to sales of its Genie brand products to Asia, particularly China.